Advertisement


Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals

2017 Genitourinary Cancers Symposium

Advertisement

Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.



Related Videos

Kidney Cancer

Sumanta K. Pal, MD, on Advanced Renal Cancer: Treatment Challenges

Sumanta K. Pal, MD, of the City of Hope, summarizes a session he co-chaired on the opportunities and challenges in systemic therapy for advanced renal cancer, including imaging as a biomarker of response and optimal selection of front-line treatments. (General Session 9)

Solid Tumors

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response

Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Kidney Cancer

W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition

W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.

Issues in Oncology

Brian C. Allen, MD, on Assessing Tumor Response: Standard-of-Care vs Computer-Assisted Evaluation

Brian C. Allen, MD, of Duke University Medical Center, discusses the benefits of using a computerized process that provides step-wise guidance, decreases interpretation time, and reduces errors when measuring tumor response to treatment. (Abstract 432)

Advertisement

Advertisement




Advertisement